719297-59-3

Basic information

• Product Name: allyl 2-(6-(allyloxy)-2,7-dichloro-3-oxo-3H-xanthen-9-yl)benzoate
• Synonyms: allyl 2-(6-(allyloxy)-2,7-dichloro-3-oxo-3H-xanthen-9-yl)benzoate
• CAS NO: 719297-59-3
• Molecular Weight: 481.332
• Mol File: 719297-59-3.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: allyl 2-(6-(allyloxy)-2,7-dichloro-3-oxo-3H-xanthen-9-yl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: allyl 2-(6-(allyloxy)-2,7-dichloro-3-oxo-3H-xanthen-9-yl)benzoate(719297-59-3)
• EPA Substance Registry System: allyl 2-(6-(allyloxy)-2,7-dichloro-3-oxo-3H-xanthen-9-yl)benzoate(719297-59-3)

Safety Data

• Hazardous Substances Data: 719297-59-3(Hazardous Substances Data)

Upstream product

• 76-54-0 2',7'-dichlorofluorescein 
• 106-95-6 allyl bromide 
• 18362-80-6 2,7-dichlorofluorescein 

Downstream Products

• 1043577-67-8 Pittsburgh Yellow 
• 889663-71-2 C₃₃H₂₁Cl₂F₃O₆ 
• 889663-68-7 C₃₂H₂₂Cl₂O₇ 
• 889663-66-5 C₃₃H₂₄Cl₂O₇ 

Relevant articles and documents

A highly sensitive fluorescent chemosensor for ruthenium: Oxidation plays a triple role

Ruthenium comes to its senses: Determining how effectively ruthenium residues are removed from olefin metathesis reactions calls for an alternative evaluation method to ICP-MS. A fluorescent chemosensor for ruthenium has been developed based on an alkene oxidation reaction (see figure). This fluorescence method has a good selectivity as well as an excellent sensitivity and a 0.32 ppb detection limit. Its streamlined and high-throughput character is demonstrated by sensing residual Ru in samples containing functionalized organic compounds. Copyright

Allyl Fluorescein Ethers as Promising Fluorescent Probes for Carbon Monoxide Imaging in Living Cells

Recently, the fluorescent detection of carbon monoxide (CO) in living cells has attracted great attention. However, due to the lack of effective ways to construct fluorescent CO probes, fluorescent detection of CO in living cells is still in its infancy.

Enzyme-triggered supramolecular self-assembly of platinum prodrug with enhanced tumor-selective accumulation and reduced systemic toxicity

We report the generation of a novel self-assembled platinum (Pt) prodrug from a short peptide derivative, which acted as a substrate for the phosphatase-catalyzed dephosphorylation reaction, and a Pt(iv) complex, which could undergo supramolecular self-assembly in the presence of alkaline phosphatase, and perform controlled release of the Pt(ii) drug under the reductive conditions of tumor cells. This self-assembled prodrug showed significant antitumor growth effects on a breast cancer xenograft model based on 4T1 cells in vivo, but much lower toxicity towards the kidney, liver, spleen and other major organs than the free cisplatin drug in mice. Such improved antitumor efficacy could be ascribed to the localized and sustained release of the Pt(ii) anticancer drug from the supramolecular self-assembly of the Pt(iv) prodrug, which was triggered by phosphatases in tumor sites.